Plasmodium dihydroorotate dehydrogenase: A promising target for novel anti-malarial chemotherapy

Infectious Disorders - Drug Targets

Volumn 10, Issue 3, 2010, Pages 226-239

  Phillips, Margaret A ^a   Rathod, Pradipsinh K ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Dihydroorotate dehydrogenase; Drug discovery; Malaria; Plasmodium; Pyrimidine biosynthesis

Indexed keywords

AMIDE; ANTIMALARIAL AGENT; BENZAMIDE DERIVATIVE; DIHYDROOROTATE DEHYDROGENASE; DSM 74; NAPHTHYL GROUP; PYRIMIDINE; PYRIMIDINE DERIVATIVE; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; GENOME; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; MALARIA; MORBIDITY; MORTALITY; NONHUMAN; PARASITEMIA; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

EID: 77953773127     PISSN: 18715265     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152610791163336     Document Type: Article

References (87)

1. Greenwood, B.M.; Fidock, D.A.; Kyle, D.E.; Kappe, S.H.; Alonso, P.L.; Collins, F.H.; Duffy, P.E. Malaria: progress, perils, and prospects for eradication. J. Clin. Invest., 2008, 118(4), 1266-1276.
2. Guerra, C.A.; Gikandi, P.W.; Tatem, A.J.; Noor, A.M.; Smith, D.L.; Hay, S.I.; Snow, R.W. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med., 2008, 5(2), e38.
3. Craft, J.C. Challenges facing drug development for malaria. Curr. Opin. Microbiol., 2008, 11(5), 428-433.
4. White, N.J. Antimalarial drug resistance. J. Clin. Invest., 2004, 113(8), 1084-1092.
5. Rathod, P.K.; McErlean, T.; Lee, P.C. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA, 1997, 94(7), 9389-9393.
6. White, N.J. The role of anti-malarial drugs in eliminating malaria. Malar. J., 2008, 11(7) (Suppl 1), S8.
7. Rosenthal, P.J. Artesunate for the treatment of severe falciparum malaria. N. Engl. J. Med., 2008, 358(17), 1829-1836.
8. Dondorp, A.M.; Nosten, F.; Yi, P.; Das, D.; Phyo, A.P.; Tarning, J.; Lwin, K.M.; Ariey, F.; Hanpithakpong, W.; Lee, S.J.; Ringwald, P.; Silamut, K.; Imwong, M.; Chotivanich, K.; Lim, P.; Herdman, T.; An, S.S.; Yeung, S.; Singhasivanon, P.; Day, N.P.; Lindegardh, N.; Socheat, D.; White, N.J. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med., 2009, 361(5), 455-467.
9. Gelb, M.H. Drug discovery for malaria: a very challenging and timely endeavor. Curr. Opin. Chem. Biol., 2007, 11(4), 440-445.
10. Olliaro, P.; Wells, T.N. The global portfolio of new antimalarial medicines under development. Clin. Pharmacol. Ther., 2009, 85(6), 584-595.
11. Gardner, M.J.; Hall, N.; Fung, E.; White, O.; Berriman, M.; Hyman, R.W.; Carlton, J. M.; Pain, A.; Nelson, K.E.; Bowman, S.; Paulsen, I.T.; James, K.; Eisen, J. A.; Rutherford, K.; Salzberg, S.L.; Craig, A.; Kyes, S.; Chan, M.S.; Nene, V.; Shallom, S.J.; Suh, B.; Peterson, J.; Angiuoli, S.; Pertea, M.; Allen, J.; Selengut, J.; Haft, D.; Mather, M.W.; Vaidya, A.B.; Martin, D.M.; Fairlamb, A. H.; Fraunholz, M.J.; Roos, D.S.; Ralph, S.A.; McFadden, G.I.; Cummings, L.M.; Subramanian, G.M.; Mungall, C.; Venter, J.C.; Carucci, D.J.; Hoffman, S.L.; Newbold, C.; Davis, R.W.; Fraser, C.M.; Barrell, B. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature, 2002, 419(6906), 498-511.
12. Fry, M.; Pudney, M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem. Pharmacol., 1992, 43(7), 1545-1553.
13. Mather, M.W.; Darrouzet, E.; Valkova-Valchanova, M.; Cooley, J.W.; McIntosh, M.T.; Daldal, F.; Vaidya, A.B. Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system. J. Biol. Chem., 2005, 280(29), 27458-27465.
14. Srivastava, I.; Morrisey, J.; Darrouzet, E.; Daldal, F.; Vaidya, A. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol. Microbiol., 1999, 33(4), 704-711.
15. Srivastava, I.; Rottenberg, H.; Vaidya, A. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J. Biol. Chem., 1997, 272(7), 3961-3966.
16. Hyde, J.E. Targeting purine and pyrimidine metabolism in human apicomplexan parasites. Curr. Drug Targets, 2007, 8(1), 31-47.
17. Seymour, K.K.; Yeo, A.E.; Rieckmann, K.H.; Christopherson, R.I. dCTP levels are maintained in Plasmodium falciparum subjected to pyrimidine deficiency or excess. Ann. Trop. Med. Parasitol., 1997, 91(6), 603-9.
18. Ittarat, I.; Asawamahasakda, W.; Meshnick, S.R. The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase. Exp. Parasitol., 1994, 79(1), 50-56.
19. Painter, H. J.; Morrisey, J. M.; Mather, M. W.; Vaidya, A. B. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature, 2007, 446(7131), 88-91.
20. Vaidya, A.B.; Mather, M.W. Mitochondrial Evolution and Functions in Malaria Parasites. Annu. Rev. Microbiol., 2009, 63, 249-267.
21. Jiang, L.; Lee, P.C.; White, J.; Rathod, P.K. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum. Antimicrob. Agents Chemother., 2000, 44(4), 1047-1050.
22. Rathod, P.K.; Khatri, A.; Hubbert, T.; Milhous, W.K. Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro. Antimicrobial. Agents Chemother., 1989, 33(7), 1090-1094.
23. Rathod, P.K.; Leffers, N.P.; Young, R.D. Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum. Antimicrobial. Agents Chemother., 1992, 36(4), 704-711.
24. Rathod, P.K.; Reshmi, S. Suceptibility of Plasmodium falciparum to a combination of thymidine and ICI D1694, a quinazoline antifolate directed at thymidylate synthase. Antimicrobial. Agents Chemother., 1994, 38(3), 476-480.
25. Rathod, P.K.; Reyes, P., Orotidylate-metabolizing enzymes of the human malarial parasite, Plasmodium falciparum, differ from host cell enzymes. J. Biol. Chem., 1983, 258(5), 2852-2855.
26. Reyes, P.; Rathod, P.K.; Sanchez, D.J.; Mrema, J.E.; Rieckmann, K.N.; Heidrich, H.G. Enzymes of purine and pyrimidine metabolism from the human malaria parasite. Plasmodium falciparum. Mol. Biochem. Parasitol., 1982, 5(5), 275-290.
27. Krungkrai, J. Purification, characterization and localization of mitochondrial dihydroorotate dehydrogenase in Plasmodium falciparum, human malarial parasite. Biochim. Biophys. Acta, 1995, 1243(3), 351-360.
28. Krungkrai, J.; Krungkrai, S.R.; Phakanont, K. Antimalarial activity of orotate analogs that inhibit dihdroorotase and dihydroorotate dehydrogenase. Biochem. Pharmacol., 1992, 43(6), 1295-1301.
29. LeBlanc, S.B.; Wilson, C.M. The dihydroorotate dehydrogenase gene homologue of Plasmodium falciparum. Mol. Biochem. Parasitol., 1993, 60(2), 349-352.
30. Nara, T.; Hshimoto, T.; Aoki, T. Evolutionary implications of the mosaic pyrimidine-biosynthetic pathway in eukaryotes. Gene, 2000, 257(2), 209-222.
31. Gutteridge, W.E.; Trigg, P.I. Incorporatin of radioactive precursors into DNA and RNA of Plasmodium knowlesi. J. Protozool., 1970, 17(1), 89-96.
32. Hopkins, A.L.; Groom, C.R. The druggable genome. Nat. Rev. Drug Discov., 2002, 1(9), 727-730.
33. Aguero, F.; Al-Lazikani, B.; Aslett, M.; Berriman, M.; Buckner, F.S.; Campbell, R.K.; Carmona, S.; Carruthers, I.M.; Chan, A.W.; Chen, F.; Crowther, G.J.; Doyle, M.A.; Hertz-Fowler, C.; Hopkins, A.L.; McAllister, G.; Nwaka, S.; Overington, J.P.; Pain, A.; Paolini, G.V.; Pieper, U.; Ralph, S.A.; Riechers, A.; Roos, D. S.; Sali, A.; Shanmugam, D.; Suzuki, T.; Van Voorhis, W.C.; Verlinde, C.L.,Genomic-scale prioritization of drug targets: the TDR Targets database. Nat. Rev. Drug. Discov., 2008, 7(11), 900-907.
34. Goldenberg, M.M. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. Clin. Ther., 1999, 21(11), 1837-1852.
35. Herrmann, M.L.; Schleyerbach, R.; Kirschbaum, B.J. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology, 2000, 47(2-3), 273-289.
36. Olsen, N.J.; Stein, C.M. New drugs for rheumatoid arthritis. N. Engl. J. Med., 2004, 350(21), 2167-2179.
37. Davis, J.P.; Cain, G.A.; Pitts, W.J.; Magolda, R.L.; Copeland, R.A. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry, 1996, 35(4), 1270-1273.
38. Williamson, R. A.; Yea, C. M.; Robson, P. A.; Curnock, A. P.; Gadher, S.; Hambleton, A. B.; Woodward, K.; Bruneau, J. M.; Hambleton, P.; Moss, D.; Thomson, T. A.; Spinella-Jaegle, S.; Morand, P.; Courtin, O.; Sautes, C.; Westwood, R.; Hercend, T.; Kuo, E. A.; Ruuth, E. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem., 1995, 270(38), 22467-22472.
39. Greene, S.; Watanabe, K.; Braatz-Trulson, J.; Lou, L. Inhibition of dihydroorotate dehydrogenase by the immunosppressive agent leflunomide. Biochem. Pharmacol., 1995, 50, 861-867.
40. Ruckemann, K.; Fairbanks, L.D.; Carrey, E.A.; Hawrylowicz, C.M.; Richards, D.F.; Kirschbaum, B.; Simmonds, H.A. Leflunomide inhibits pyrimidine de novo synthesis in mitogenstimulated T-lymphocytes from healthy humans. J. Biol. Chem., 1998, 273(34), 21682-21691.
41. Kuo, E.A.; Hambleton, P.T.; Kay, D.P.; Evans, P.L.; Matharu, S.S.; Little, E.; McDowall, N.; Jones, C.B.; Hedgecock, C.J.; Yea, C.M.; Chan, A.W.; Hairsine, P.W.; Ager, I.R.; Tully, W.R.; Williamson, R.A.; Westwood, R. Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitiors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl) phenyl]propenamide and related compounds. J. Med. Chem., 1996, 39(23), 4608-4621.
42. Knecht, W.; Loffler, M. Redoxal as a new lead structure for dihydroorotate dehydrogenase inhibitors: a kinetic study of the inhibition mechanism. FEBS Lett., 2000, 467(1), 27-30.
43. Deguchi, M.; Kishino, J.; Hattori, M.; Furue, Y.; Yamamoto, M.; Mochizuki, I.; Iguchi, M.; Hirano, Y.; Hojou, K.; Nagira, M.; Nishitani, Y.; Okazaki, K.; Yasui, K.; Arimura, A. Suppression of immunoglobulin production by a novel dihydroorotate dehydrogenase inhibitor, S-2678. Eur. J. Pharmacol., 2008, 601(1-3), 163-170.
44. Chen, S.F.; Ruben, R.L.; Dexter, D.L. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res., 1986, 46(10), 5014-5019.
45. Peters, G.J.; Schwartsmann, G.; Nadal, J.C.; Laurensse, E.J.; van Groeningen, C.J.; van der Vijgh, W.J.; Pinedo, H.M. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients. Cancer Res., 1990, 50(15), 4644-4649.
46. Batt, D.G.; Petraitis, J.J.; Sherk, S.R.; Copeland, R.A.; Dowling, R.L.; Taylor, T.L.; Jones, E.A.; Magolda, R.L.; Jaffee, B.B. Heteroatom-and carbon-linked biophenyl analogs of brequinar as immunosuppressive agents. Bioorg. Med. Chem. Lett., 1998, 8(13), 1745-1750.
47. Batt, D.G.; Copeland, R.A.; Dowling, R.L.; Gardner, T.L.; Jones, E.A.; Orwat, M.J.; Pinto, D.J.; Pitts, W.J.; Magolda, R.L.; Jaffee, B.D. Immunosuppressive structure-activity relationships of Brequinar and related cinchoninic acid derivatives. Bioorg. Med. Chem. Lett., 1995, 5(14), 1549-1554.
48. Pitts, W.J.; Jetter, J.W.; Pinto, D.J.; Orwat, M.J.; Batt, D.G.; Sherk, S.R.; Petraitis, J.J.; Jacobson, I.C.; Copeland, R.A.; Dowling, R.L.; Jaffee, B.D.; Gardner, T.;L. Jones, E.A.; Magolda, R.L. Structureactivity relationships of some tetracyclic heterocycles related to the immunosuppressive agent brequinar sodium. Bioorg. and Med. Chem. Lett., 1998, 8(3), 307-312.
49. Liu, S.; Neidhardt, E. A.; Grossman, T. H.; Ocain, T.; Clardy, J. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure, 2000, 8(1), 25-33.
50. Malmquist, N.A.; Baldwin, J.; Phillips, M.A. Detergent-dependent kinetics of truncated Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem., 2007, 282(17), 12678-12686.
51. Arakaki, T.L.; Buckner, F.S.; Gillespie, J.R.; Malmquist, N.A.; Phillips, M.A.; Kalyuzhniy, O.; Luft, J.R.; Detitta, G.T.; Verlinde, C.L.; Van Voorhis, W.C.; Hol, W.G.; Merritt, E.A. Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol. Microbiol., 2008, 68(1), 37-50.
52. Nagy, M.; Lacroute, F.; Thomas, D. Divergent evolution of pyrimidine biosynthesis between anaerobic and aerobic yeasts. Proc. Natl. Acad. Sci. USA, 1992, 89(19), 8966-8970.
53. Bjornberg, O.; Jordan, D. B.; Palfey, B.A.; Jensen, K.F. Dihydrooxonate is a substrate of dihydroorotate dehydrogenase (DHOD) providing evidence for involvement of cysteine and serine residues in base catalysis. Arch. Biochem. Biophys., 2001, 391(2), 286-294.
54. Bjornberg, O.; Rowland, P.; Larsen, S.; Jensen, K.F. Active site of dihydroorotate dehydrogenase A from Lactococcus lactis investigated by chemical modification and mutagenesis. Biochemistry, 1997, 36(51), 16197-16205.
55. Wolfe, A.E.; Thymark, M.; Gattis, S.G.; Fagan, R.L.; Hu, Y.C.; Johansson, E.; Arent, S.; Larsen, S.; Palfey, B.A. Interaction of benzoate pyrimidine analogues with class 1A dihydroorotate dehydrogenase from Lactococcus lactis. Biochemistry, 2007, 46(19), 5741-5753.
56. Marcinkeviciene, J.; Tinney, L.M.; Wang, K.H.; Rogers, M.J.; Copeland, R.A. Dihydroorotate dehydrogenase B of Enterococcus faecalis. Characterization and insights into chemical mechanism. Biochemistry, 38(40), 13129-13137.
57. Rowland, P.; Norager, S.; Jensen, K.F.; Larsen, S. Structure of roorotate dehydrogenase B: electron transfer between two flavin groups bridged by a iron-sulphur cluster. Structure, 2000, 8(12), 1227-1238.
58. Copeland, R.A.; Davis, J.P.; Dowling, R.L.; Lombardo, D.; Murphy, K.B.; Patterson, T.A. Recombinant human dihydroorotate dehydrogenase: expression, purification, and characterization of a catalytically functional truncated enzyme. Arch. Biochem. Biophys., 1995, 323(1), 79-86.
59. Hurt, D. E.; Widom, J.; Clardy, J. Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor. Acta Crystallogr. D Biol. Crystallogr., 2006, 62(Pt 3), 312-323.
60. Palfey, B.A.; Bjornberg, O.; Jensen, K.F. Insight into the chemistry of flavin reduction and oxidation in Escherichia coli dihydroorotate dehydrogenase obtained by rapid reaction studies. Biochemistry, 2001, 40(14), 4381-4390.
61. Norager, S.; Jensen, K. F.; Bjornberg, O.; Larsen, S.,E. coli dihydroorotate dehydrogenase reveals structural and functional distinctions between different classes of dihydroorotate dehydrogenases. Structure, 2002, 10(9), 1211-1223.
62. Baldwin, J.; Farajallah, A.M.; Malmquist, N.A.; Rathod, P.K.; Phillips, M.A. Malarial dihydroorotate dehydrogenase: substrate and inhibitor specificity. J. Biol. Chem., 2002, 277(44), 41827-41834.
63. Davies, M.; Heikkila, T.; McConkey, G.A.; Fishwick, C.W.; Parsons, M.R.; Johnson, A.P. Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J. Med. Chem., 2009, 52(9), 2683-2693.
64. Baumgartner, R.; Walloschek, M.; Kralik, M.; Gotschlich, A.; Tasler, S.; Mies, J.; Leban, J. Dual binding mode of a novel series of DHODH inhibitors. J. Med. Chem., 2006, 49(4), 1239-1247.
65. Walse, B.; Dufe, V.T.; Svensson, B.; Fritzson, I.; Dahlberg, L.; Khairoullina, A.; Wellmar, U.; Al-Karadaghi, S. The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites. Biochemistry, 2008, 47(34), 8929-8936.
66. Deng, X.; Gujjar, R.; El Mazouni, F.; Kaminsky, W.; Malmquist, N.A.; Goldsmith, E.J.; Rathod, P.K.; Phillips, M.A. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds. J. Biol. Chem., 2009, 284(39), 26999-27009.
67. Knecht, W.; Loffler, M. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Biochem. Pharmacol., 1998, 56(9), 1259-1264.
68. Chen, S. F.; Perrella, F. W.; Behrens, D. L.; Papp, L. M., Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium. Cancer Res., 1992, 52 (13), 3521-3527.
69. Marcinkeviciene, J.; Rogers, M.J.; Kopcho, L.; Jiang, W.; Wang, K.; Murphy, D.; Lippy, J.; Link, S.; Chung, T.D.; Hobbs, F.; Haque, T.S.; Trainor, G.L.; Slee, A.; Stern, A.M.; Copeland, R.A. Selective inhibition of bacterial dihydroorotate dehydrogenases by thiadiazolidinediones. Biochem. Pharmacol., 2000, 60(3), 339-342.
70. Copeland, R.A.; Marcinkeviciene, J.; Haque, T.S.; Kopcho, L. M.; Jiang, W.; Wang, K.; Ecret, L. D.; Sizemore, C.; Amsler, K. A.; Foster, L.; Tadesse, S.; Combs, A. P.; Stern, A. M.; Trainor, G. L.; Slee, A.; Rogers, M. J.; Hobbs, F. Helicobacter pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis. J. Biol. Chem., 2000, 275(43), 33373-33378.
71. Haque, T.; Tadesse, S.; Marcinkeviciene, J.; Rogers, J.; Sizemore, C.; Kopcho, L.; Amsler, K.; Ecret, L.; Zhan, D.; Hobbs, F.; Slee, A.; Trainor, G.; Stern, A.; Copeland, R.A.; Combs, A. Parallel synthesis of potent, pyrazole-based inhibitors of Helicobacter pylori dihydroorotate dehydrogenase. J. Med. Chem., 2002, 45(21), 4669-4678.
72. Baldwin, J.; Michnoff, C.H.; Malmquist, N.A.; White, J.; Roth, M.G.; Rathod, P.K.; Phillips, M.A. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem., 2005, 280(23), 21847-21853.
73. Phillips, M.A.; Gujjar, R.; Malmquist, N.A.; White, J.; El Mazouni, F.; Baldwin, J.; Rathod, P.K. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite, Plasmodium falciparum. J. Med. Chem., 2008, 51(12), 3649-3653.
74. Gujjar, R.; Marwaha, A.; El Mazouni, F.; White, J.; White, K.L.; Creason, S.; Shackleford, D.M.; Baldwin, J.; Charman, W.N.; Buckner, F.S.; Charman, S.; Rathod, P.K.; Phillips, M.A. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J. Med. Chem., 2009, 52(7), 1864-1872.
75. Patel, V.; Booker, M.; Kramer, M.; Ross, L.; Celatka, C.A.; Kennedy, L.M.; Dvorin, J. D.; Duraisingh, M.T.; Sliz, P.; Wirth, D.F.; Clardy, J. Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem., 2008, 283(50), 35078-35085.
76. Boa, A.N.; Canavan, S.P.; Hirst, P.R.; Ramsey, C.; Stead, A.M. W.; McConkey, G.A. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase. Bioorg. Med. Chem., 2005, 13(6), 1945-1967.
77. Heikkilae, T.; Thirumalairajan, S.; Davies, M.; Parsons, M.R.; McConkey, A.G.; Fishwick, C.W.; Johnson, A.P. The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg. Med. Chem. Lett., 2006, 16(1), 88-92.
78. Heikkila, T.; Ramsey, C.; Davies, M.; Galtier, C.; Stead, A. M.; Johnson, A.P.; Fishwick, C.W.; Boa, A.N.; McConkey, G.A. Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J. Med. Chem., 2007, 50(2), 186-191.
79. McLean, J.E.; Neidhardt, E.A.; Grossman, T.H.; Hedstrom, L. Multiple inhibitor analysis of Brequinar and Leflunomide binding sites on human dihydroorotate dehydrogenase. Biochemistry, 2001, 40(7), 2194-2200.
80. Malmquist, N.A.; Gujjar, R.; Rathod, P.K.; Phillips, M.A., Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase. Biochemistry, 2008, 47(8), 2466-2475.
81. Krungkrai, J.; Krungkrai, S.R.; Supuran, C.T. Carbonic anhydrase inhibitors: inhibition of Plasmodium falciparum carbonic anhydrase with aromatic/heterocyclic sulfonamides- and studies. Bioorg. Med. Chem. Lett., 2008, 18(20), 5466-5471.
82. Krungkrai, S.R.; Wutipraditkul, N.; Krungkrai, J. Dihydroorotase of human malarial parasite Plasmodium falciparum differs from host enzyme. Biochem. Biophys. Res. Commun., 2008, 366(3), 821-826.
83. Meza-Avina, M. E.; Wei, L.; Buhendwa, M. G.; Poduch, E.; Bello, A. M.; Pai, E. F.; Kotra, L.P. Inhibition of orotidine 5'-monophosphate decarboxylase and its therapeutic potential. Mini Rev. Med. Chem., 2008, 8(3), 239-247.
84. Krungkrai, S.R.; DelFraino, B.J.; Smiley, J.A.; Prapunwattana, P.; Mitamura, T.; Horii, T.; Krungkrai, J. A novel enzyme complex of orotate phosphoribosyltransferase and orotidine 5'-monophosphate decarboxylase in human malaria parasite Plasmodium falciparum: physical association, kinetics, and inhibition characterization. Biochemistry, 2005, 44(5), 1643-1652.
85. Langley, D.B.; Shojaei, M.; Chan, C.; Lok, H.C.; Mackay, J.P.; Traut, T.W.; Guss, J.M.; Christopherson, R.I. Structure and inhibition of orotidine 5'-monophosphate decarboxylase from Plasmodium falciparum. Biochemistry, 2008, 47(12), 3842-3854.
86. Bello, A.M.; Poduch, E.; Liu, Y.; Wei, L.; Crandall, I.; Wang, X.; Dyanand, C.; Kain, K. C.; Pai, E.F.; Kotra, L.P. Structure-activity relationships of C6-uridine derivatives targeting plasmodia orotidine monophosphate decarboxylase. J. Med. Chem., 2008, 51(3), 439-448.
87. Zhang, Y.; Luo, M.; Schramm, V.L. Transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases. J. Am. Chem. Soc., 2009, 131(13), 4685-4694.